Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

Dimopoulos, M A; Kastritis, E; Michalis, E; Tsatalas, C; Michael, M; Pouli, A; Kartasis, Z; Delimpasi, S; Gika, D; Zomas, A; Roussou, M; Konstantopoulos, K; Parcharidou, A; Zervas, K; Terpos, E.

Ann Oncol ; 23(3): 722-729, 2012 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-21652580

2.

Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study.

Lafaras, C; Mandala, E; Verrou, E; Platogiannis, D; Barbetakis, N; Bischiniotis, T; Zervas, K.

Ann Oncol ; 19(10): 1765-9, 2008 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-18480066

3.

Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.

Eleutherakis-Papaiakovou, V; Bamias, A; Gika, D; Simeonidis, A; Pouli, A; Anagnostopoulos, A; Michali, E; Economopoulos, T; Zervas, K; Dimopoulos, M A.

Leuk Lymphoma ; 48(2): 337-41, 2007 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-17325894

4.

Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report.

Tzilves, D; Gatopoulou, A; Zervas, K; Katodritou, E; Patakiouta, F; Tarpagos, A; Katsos, I.

World J Gastroenterol ; 13(13): 2011-3, 2007 Apr 07.

Artículo en Inglés | MEDLINE | ID: mdl-17461509

5.

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.

Terpos, E; Mihou, D; Szydlo, R; Tsimirika, K; Karkantaris, C; Politou, M; Voskaridou, E; Rahemtulla, A; Dimopoulos, M A; Zervas, K.

Leukemia ; 19(11): 1969-76, 2005 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-16079895

6.

Anaplastic myeloma.

Zervas, K; Constantinou, N; Karakantza, M; Tsigalidou-Balla, V.

Leuk Lymphoma ; 16(5-6): 515-8, 1995 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-7787758

7.

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Katodritou, E; Gastari, V; Verrou, E; Hadjiaggelidou, C; Varthaliti, M; Georgiadou, S; Laschos, K; Xirou, P; Yiannaki, E; Constantinou, N; Markala, D; Zervas, K.

Leuk Res ; 33(8): 1137-40, 2009 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-19250676

8.

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

Kastritis, E; Zervas, K; Symeonidis, A; Terpos, E; Delimbassi, S; Anagnostopoulos, N; Michali, E; Zomas, A; Katodritou, E; Gika, D; Pouli, A; Christoulas, D; Roussou, M; Kartasis, Z; Economopoulos, T; Dimopoulos, M A.

Leukemia ; 23(6): 1152-7, 2009 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-19225533

9.

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.

Zervas, K; Mihou, D; Katodritou, E; Pouli, A; Mitsouli, C H; Anagnostopoulos, A; Delibasi, S; Kyrtsonis, M C; Anagnostopoulos, N; Terpos, E; Zikos, P; Maniatis, A; Dimopoulos, M A.

Ann Oncol ; 18(8): 1369-75, 2007 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-17693650

10.

Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.

Zervas, K; Pouli, A; Perifanis, V; Papanastasiou, K; Chatziyianni, M; Mitsouli, C; Maniatis, A.

Eur J Haematol ; 57(2): 142-8, 1996 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-8856091

11.

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.

Hatjiharissi, E; Terpos, E; Papaioannou, M; Hatjileontis, C; Kaloutsi, V; Galaktidou, G; Gerotziafas, G; Christakis, J; Zervas, K.

Hematol Oncol ; 22(4): 159-68, 2004 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-15991268

12.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

Zervas, K; Dimopoulos, M A; Hatzicharissi, E; Anagnostopoulos, A; Papaioannou, M; Mitsouli, Ch; Panagiotidis, P; Korantzis, J; Tzilianos, M; Maniatis, A.

Ann Oncol ; 15(1): 134-8, 2004 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-14679133

13.

Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.

Zervas, K; Pouli, A; Gregoraki, B; Anagnostopoulos, N; Dimopoulos, M A; Bourantas, K; Tzilianos, M; Barbarousi, D; Venetis, E; Vyniou, N; Maniatis, A.

Eur J Haematol ; 66(1): 18-23, 2001 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-11168503

14.

Thalidomide and dexamethasone combination for refractory multiple myeloma.

Dimopoulos, M A; Zervas, K; Kouvatseas, G; Galani, E; Grigoraki, V; Kiamouris, C; Vervessou, E; Samantas, E; Papadimitriou, C; Economou, O; Gika, D; Panayiotidis, P; Christakis, I; Anagnostopoulos, N.

Ann Oncol ; 12(7): 991-5, 2001 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-11521808

15.

Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.

Dimopoulos, M A; Hamilos, G; Zervas, K; Symeonidis, A; Kouvatseas, G; Roussou, P; Gika, D; Karmiris, T; Bourantas, K; Zomas, A; Mitsouli, C; Xilouri, I; Vervessou, E; Matsis, K; Anagnostopoulos, N; Economopoulos, T.

Ann Oncol ; 14(8): 1299-305, 2003 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-12881396

16.

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

Dimopoulos, M A; Pouli, A; Zervas, K; Grigoraki, V; Symeonidis, A; Repoussis, P; Mitsouli, C; Papanastasiou, C; Margaritis, D; Tokmaktsis, A; Katodritou, I; Kokkini, G; Terpos, E; Vyniou, N; Tzilianos, M; Chatzivassili, A; Kyrtsonis, M C; Panayiotidis, P; Maniatis, A.

Ann Oncol ; 14(7): 1039-44, 2003 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-12853344

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: